Clovis Oncology (CLVS) Received FDA Approval for Rubraca as Monotherapy Treatment for Patients with BRCA1/2-Mutant, mCRPC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Clovis Oncology (CLVS) Received FDA Approval for Rubraca as Monotherapy Treatment for Patients with BRCA1/2-Mutant, mCRPC
May 19, 2020 5:41 AM EDT
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the pricing of 11,090,000 shares of its common stock in an underwritten public offering at a price to the public of $8.05 per share, before underwriting discounts and commissions. Clovis Oncology also granted to the underwriters a 30-day option... More
May 18, 2020 7:47 AM EDT
H.C. Wainwright analyst Edward Wright raised the price target on Clovis Oncology (NASDAQ: CLVS) to $33.00 (from $29.00) while maintaining a Buy rating.
The analyst commented, "On Friday, Clovis announced that the FDA granted accelerated approval for Rubraca in patients with BRCA1/2-mutant, metastatic castration-resistant prostate cancer (mCRPC) patients who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The label was as we had expected with no surprises. Rubraca is Clovis oral,... More
